

# Report on the Chinese Biomedical Industry 2019-2023

<https://marketpublishers.com/r/R5E45752993EN.html>

Date: March 2019

Pages: 306

Price: US\$ 5,000.00 (Single User License)

ID: R5E45752993EN

## Abstracts

It takes 3-5 business days to dispatch the report after the purchase is made.

The biomedical industry is a combination of the biotechnology industry and the medical industry. While the Chinese biomedical industry was created much later than that of other countries, the industry has become a main consumer market due to advancements in technology and increasing living standards, with many biomedical companies relocating to the Chinese market.

Medical reforms in the country have caused the biomedical industry to become a key part of the Chinese government's plans. The biomedical industry is expected to welcome an extended period of growth in the following years, with the industry achieving a scale of XX billion CNY in 2018 and expected to achieve of a scale of XX billion CNY in 2023. The aging population, the increased demand for improved healthcare and increased spending are expected to become some of the key drivers of growth in this market.

## Contents

### CHAPTER 1 GLOBAL BIOMEDICAL INDUSTRY DEVELOPMENT ANALYSIS

- 1.1 Global Biomedical Industry development
  - 1.1.1 Industry developments
  - 1.1.2 Development scale
  - 1.1.3 Mergers and Acquisitions
  - 1.1.4 Changes within the Industry
  - 1.1.5 Pharmaceutical companies' sales data
  - 1.1.6 Technological breakthroughs
    - 1.1.6.1 USA
    - 1.1.6.2 UK
    - 1.1.6.3 Canada
    - 1.1.6.4 Germany
    - 1.1.6.5 France
    - 1.1.6.6 Russia
    - 1.1.6.7 Korea
    - 1.1.6.8 Japan
    - 1.1.6.9 Brazil
    - 1.1.6.10 Israel
- 1.2 Global pharmaceutical companies research investments
  - 1.2.1 Pfizer
  - 1.2.2 Roche
  - 1.2.3 MSD
  - 1.2.4 Novartis
  - 1.2.5 Johnson and Johnson
  - 1.2.6 GSK
  - 1.2.7 Sanofi Aventis
  - 1.2.8 AstraZeneca
  - 1.2.9 Lilly and Company
- 1.3 Global Biomedical industry clusters
  - 1.3.1 Typical clusters
  - 1.3.2 Typical biomedical clusters worldwide
    - 1.3.2.1 US
    - 1.3.2.2 UK
    - 1.3.2.3 India
    - 1.3.2.4 Sweden
    - 1.3.2.5 Japan

- 1.3.3 Common characteristics
- 1.4 Key development factors
  - 1.4.1 National policy support
  - 1.4.2 Innovation
  - 1.4.3 A strong financial system
  - 1.4.4 Clustering effect created by leading companies
  - 1.4.5 Integration with the latest technologies
- 1.5 Key global biomedical industry clusters
  - 1.5.1 UK Biomedical Technology cluster
  - 1.5.2 USA Maryland Biomedcial cluster
  - 1.5.3 Ille-de-France
  - 1.5.4 Oresund Strait

## **CHAPTER 2 CHINESE BIOMEDICAL INDUSTRY DEVELOPMENTS**

- 2.1 Macroeconomic environment
  - 2.1.1 GDP growth
  - 2.1.2 Industry developments
  - 2.1.3 Social fixed asset investments
  - 2.1.4 Social consumables retail figures
  - 2.1.5 Citizens' income data
  - 2.1.6 Citizens' spending data
  - 2.1.7 Foreign trade
- 2.2 Development policies
  - 2.2.1
  - 2.2.2
  - 2.2.3
  - 2.2.4
  - 2.2.5
- 2.3 Chinese biomedical industry clusters social analysis
  - 2.3.1 Population
  - 2.3.2 Urbanization rates
  - 2.3.3 Population aging
  - 2.3.4 Resources
- 2.4 Technological environment analysis
  - 2.4.1 Biomedical technology levels and characteristics
  - 2.4.2 Biomedical technology development trends

## **CHAPTER 3 CHINESE BIOMEDICAL INDUSTRY DEVELOPMENTS**

- 3.1 Biomedical market developments
  - 3.1.1 Development overview
  - 3.1.2 Market scale
  - 3.1.3 Core fields
  - 3.1.4 Development direction
- 3.2 Outsourcing developments
  - 3.2.1 Outsourcing services overview
  - 3.2.2 R&D outsourcing
  - 3.2.3 Outsourcing and drug innovations
  - 3.2.4 Outsourcing trends
  - 3.2.5 Outsourcing strategies
- 3.3 Main aspects of biomedical engineering
  - 3.3.1 Fermentation engineering market analysis
    - 3.3.1.1 Market overview
    - 3.3.1.2 Market analysis
    - 3.3.1.3 Market development potential
  - 3.3.2 Cell engineering market development analysis
    - 3.3.2.1 Market development overview
    - 3.3.2.2 Applications analysis
    - 3.3.2.3 Development prospects
  - 3.3.3 Genetic engineering market development
    - 3.3.3.1 Development overview
    - 3.3.3.2 Industrialized development overview
    - 3.3.3.3 Industrialized development tactics
- 3.4 Challenges and strategies
  - 3.4.1 Challenges
  - 3.4.2 Lessons and experiences
  - 3.4.3 Development advice

## **CHAPTER 4 CHINESE BIOMEDICAL MANUFACTURING INDUSTRY DATA ANALYSIS**

- 4.1 Industry development
  - 4.1.1 Development characteristics
  - 4.1.2 Industry overview
  - 4.1.3 Public companies in the industry
- 4.2 Development scale analysis
  - 4.2.1 Company growth analysis

- 4.2.2 Financial growth
- 4.2.3 Sales growth
- 4.2.4 Profit growth
- 4.3 Operational efficiency
  - 4.3.1 Development repayment capability
  - 4.3.2 Profitability
  - 4.3.3 Operational capability

## **CHAPTER 5 CHINESE BIOMEDICAL SEGMENT MARKETS DEVELOPMENT ANALYSIS**

- 5.1 Vaccines
  - 5.1.1 Chinese vaccines are WHO certified
  - 5.1.2 Industry overview
  - 5.1.3 Supply and Demand
    - 5.1.3.1 Main manufacturers
    - 5.1.3.2 2016 Wholesale overview
    - 5.1.3.3 2017 Wholesale overview
    - 5.1.3.4 2018 Wholesale overview
    - 5.1.3.5 Market scale
    - 5.1.3.6 Technological environment
    - 5.1.3.7 Political environment
  - 5.1.4 Type 1 Vaccine market supply and demand
    - 5.1.4.1 Development overview
    - 5.1.4.2 Development trends
    - 5.1.4.3 Market size
  - 5.1.5 Type II vaccine market supply and demand
    - 5.1.5.1 Market development overview
    - 5.1.5.2 Market scale
  - 5.1.6 Competitiveness analysis
    - 5.1.6.1 Key competing factors
    - 5.1.6.2 Marketization rates
    - 5.1.6.3 Product line comparisons
- 5.2 Diagnostics kits
  - 5.2.1 Market development
  - 5.2.2 Market scale
  - 5.2.3 IVD
    - 5.2.3.1 IVD development overview
    - 5.2.3.2 Market scale

- 5.2.3.3 Market structure
- 5.2.3.4 Market competition
- 5.2.3.5 Market prospects
- 5.2.4 Market competitiveness analysis
- 5.2.5 Diagnostics market prospects
- 5.3 Blood products
  - 5.3.1 Industry development
  - 5.3.2 Supportive policies
  - 5.3.3 Demand overview
  - 5.3.4 Market scale
  - 5.3.5 Competitiveness analysis
  - 5.3.6 Industry capacity
  - 5.3.7 Main company production scale
  - 5.3.8 Product analysis
  - 5.3.9 Market competitiveness
  - 5.3.10 Medical insurance
- 5.4 Antibody engineering drugs
  - 5.4.1 Development overview
  - 5.4.2 Market scale
  - 5.4.3 Monoclonal antibody technology
  - 5.4.4 R&D and trends
  - 5.4.5 Production and application
  - 5.4.6 Domestically available products
  - 5.4.7 Antibody imitation drugs market development
  - 5.4.8 Monoclonal antibody market development prospects
- 5.5 Genetic engineering drugs
  - 5.5.1 Development overview
  - 5.5.2 R&D overview
  - 5.5.3 New drug characteristics
  - 5.5.4 Market scale
  - 5.5.5 Market growth factors
  - 5.5.6 Profitability analysis

## **CHAPTER 6 CHINESE BIOMEDICAL INDUSTRY CLUSTERS ANALYSES**

- 6.1 Biomedical industry cluster overview
  - 6.1.1 Characteristics
  - 6.1.2 Categories
    - 6.1.2.1 Resource driven

- 6.1.2.2 Manufacturing driven
- 6.1.2.3 Science and research driven
- 6.1.3 Cluster uses
  - 6.1.3.1 Increases competitiveness on national and industry levels
  - 6.1.3.2 Increased competitiveness of pharmaceutical firms within the cluster
  - 6.1.3.3 Differentiation advantages
- 6.1.4 Biomedical industry global value analysis
- 6.2 Chinese biomedical industry clusters overview
  - 6.2.1 Development overview
  - 6.2.2 Top ten technologies
  - 6.2.3 Clusters with highest potential
  - 6.2.4 List of clusters with highest development potential
  - 6.2.5 Unique clusters list
- 6.3 Cluster distribution
  - 6.3.1 Coastal areas
  - 6.3.2 Key locations
    - 6.3.2.1 Bohai Bay
    - 6.3.2.2 Yangtze River Delta
    - 6.3.2.3 Pearl River Delta
    - 6.3.2.4 Northeastern Region
  - 6.3.3 Key production facilities
    - 6.3.3.1 Beijing
    - 6.3.3.2 Shanghai
    - 6.3.3.3 Taizhou
    - 6.3.3.4 Wuhan
    - 6.3.3.5 Shenzhen
    - 6.3.3.6 Changchun
- 6.4 Other cluster developments
  - 6.4.1 Tianjin
  - 6.4.2 Chengdu
  - 6.4.3 Guangzhou
  - 6.4.4 Haerbin
  - 6.4.5 Chongqing

## **CHAPTER 7 CHINESE BIOMEDICAL INDUSTRY CORE INDUSTRY CLUSTER DEVELOPMENTS**

- .1 Liuyang Biomedical cluster
  - 7.1.1 Overview

- 7.1.2 Developments
- 7.1.3 Experiences
- 7.2 Shanghai Zhangjiang Biomedical Cluster
  - 7.2.1 Overview
  - 7.2.2 Project distribution
  - 7.2.3 Development results
- 7.3 Weifang Biomedical Cluster
  - 7.3.1 Overview
  - 7.3.2 Companies
  - 7.3.3 Beneficial policies
- 7.4 Taizhou Biomedical Cluster
  - 7.4.1 Overview
  - 7.4.2 Cluster planning
- 7.5 Suzhou Wuzhong Biomedical Cluster
  - 7.5.1 Overview
  - 7.5.2 Developments
  - 7.5.3 Experiences
- 7.6 Suzhou Biomedical Industry cluster
  - 7.6.1 Overview
  - 7.6.2 Companies
  - 7.6.3 Cluster services
- 7.7 Haerbin Limin Economic Development zone
  - 7.7.1 Development
  - 7.7.2 Basic facilities
  - 7.7.3 Beneficial policies
- 7.8 Nanjing Pukou Biomedical cluster
  - 7.8.1 Overview
  - 7.8.2 Development conditions
  - 7.8.3 Experiences
- 7.9 Xiamen Biomedical port
  - 7.9.1 Overview
  - 7.9.2 Companies
  - 7.9.3 Platform support
- 7.10 Chengdu Biomedical industry cluster
  - 7.10.1 Overview
  - 7.10.2 Development conditions
  - 7.10.3 Experiences
  - 7.10.4 Development log



## **CHAPTER 8 CHINESE BIOMEDICAL COMPANIES' COMPETITIVENESS ANALYSIS**

### **8.1 CNBG**

- 8.1.1 Overview
- 8.1.2 Corporate structure
- 8.1.3 Production capacity
- 8.1.4 Main products
- 8.1.5 Vaccine development
- 8.1.6 International cooperation
- 8.1.7 Child company operations

### **8.2 CAHIC**

- 8.2.1 Overview
- 8.2.2 Main products
- 8.2.3 Operational overview
- 8.2.4 Sales network
- 8.2.5 Competitive advantages

### **8.3 Tiantan Bio**

- 8.3.1 Overview
- 8.3.2 Main products
- 8.3.3 Operational overview
- 8.3.4 Sales network
- 8.3.5 Competitive advantages

### **8.4 Fosun**

- 8.4.1 Overview
- 8.4.2 Main products
- 8.4.3 Operational overview
- 8.4.4 Sales network
- 8.4.5 Competitive advantages
- 8.4.6 Development prospects

### **8.5 SL-Pharm**

- 8.5.1 Overview
- 8.5.2 Main products
- 8.5.3 Operational overview
- 8.5.4 Sales network
- 8.5.5 Competitive advantages

### **8.6 Shanghai Kehua Bio-engineering (SKHB)**

- 8.6.1 Overview
- 8.6.2 Main products

- 8.6.3 Operational overview
- 8.6.4 Sales network
- 8.6.5 Competitive advantages
- 8.6.6 Development strategy
- 8.7 Walvax Biotechnology
  - 8.7.1 Overview
  - 8.7.2 Main products
  - 8.7.3 Product authorization process
  - 8.7.4 Operational overview
  - 8.7.5 Competitive advantages
  - 8.7.6 Development strategies
- 8.8 Hualan Bio
  - 8.8.1 Overview
  - 8.8.2 Main products
  - 8.8.3 Operational overview
  - 8.8.4 Blood products
  - 8.8.5 Competitive advantages
  - 8.8.6 Development strategies

## **CHAPTER 9 CHINESE BIOMEDICAL INDUSTRY INVESTMENT PROSPECTS AND STRATEGIES**

- 9.1 Environmental policies for investment
  - 9.1.1 Healthcare reforms
  - 9.1.2 Pricing reforms
  - 9.1.3 13th Five Year development plans
- 9.2 Development trends and prospects
  - 9.2.1 Development direction
  - 9.2.2 Development trends
- 9.3 Market scale predictions
  - 9.3.1 Heightened R&D capabilities
  - 9.3.2 Market scale predictions
- 9.4 Investment opportunities
  - 9.4.1 Regional investment hotspots
  - 9.4.2 Investment potential analysis
  - 9.4.3 Industry investment hotspots
- 9.5 Industry investment risks
  - 9.5.1 Increased government supervision
  - 9.5.2 Technical risks

- 9.5.3 Competitive risks
- 9.6 Investment strategies and advice

## **CHAPTER 10 FINANCING AND IPO STRATEGIES**

- 10.1 Financing methods and channels analysis
  - 10.1.1 Methods and channels analysis
  - 10.1.2 Equity financing
  - 10.1.3 Government leverage
  - 10.1.4 Debt financing
  - 10.1.5 Private and foreign investments
- 10.2 Domestic IPO conditions and objectives
  - 10.2.1 Main objectives
  - 10.2.2 IPO conditions
    - 10.2.2.1 Main board IPO conditions
    - 10.2.2.2 SME board IPO conditions
    - 10.2.2.3 OTC market IPO conditions
- 10.3 Biomedical companies IPO preparations
  - 10.3.1 Necessity
  - 10.3.2 Timing
  - 10.3.3 Location
  - 10.3.4 Pre-IPO preparations
    - 10.3.4.1 General evaluations
    - 10.3.4.2 Restructuring
    - 10.3.4.3 Working with agents
    - 10.3.4.4 Criteria for choosing agents
- 10.4 IPO implementation and planning
  - 10.4.1 IPO cost planning and team creation
  - 10.4.2 Due diligence and solutions
  - 10.4.3 Restructuring problems
  - 10.4.4 IPO guidance and tips
- 10.5 IPO process inspection
  - 10.5.1 Basic IPO process
  - 10.5.2 IPO inspection details
  - 10.5.3 IPO inspection related work

## I would like to order

Product name: Report on the Chinese Biomedical Industry 2019-2023

Product link: <https://marketpublishers.com/r/R5E45752993EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R5E45752993EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970